Endothelial dysfunction in diabetes mellitus

Hadi A R Hadi, Jassim Al Suwaidi, Hadi A R Hadi, Jassim Al Suwaidi

Abstract

Diabetes mellitus is associated with an increased risk of cardiovascular disease, even in the presence of intensive glycemic control. Substantial clinical and experimental evidence suggest that both diabetes and insulin resistance cause a combination of endothelial dysfunctions, which may diminish the anti-atherogenic role of the vascular endothelium. Both insulin resistance and endothelial dysfunction appear to precede the development of overt hyperglycemia in patients with type 2 diabetes. Therefore, in patients with diabetes or insulin resistance, endothelial dysfunction may be a critical early target for preventing atherosclerosis and cardiovascular disease. Microalbuminuria is now considered to be an atherosclerotic risk factor and predicts future cardiovascular disease risk in diabetic patients, in elderly patients, as well as in the general population. It has been implicated as an independent risk factor for cardiovascular disease and premature cardiovascular mortality for patients with type 1 and type 2 diabetes mellitus, as well as for patients with essential hypertension. A complete biochemical understanding of the mechanisms by which hyperglycemia causes vascular functional and structural changes associated with the diabetic milieu still eludes us. In recent years, the numerous biochemical and metabolic pathways postulated to have a causal role in the pathogenesis of diabetic vascular disease have been distilled into several unifying hypotheses. The role of chronic hyperglycemia in the development of diabetic microvascular complications and in neuropathy has been clearly established. However, the biochemical or cellular links between elevated blood glucose levels, and the vascular lesions remain incompletely understood. A number of trials have demonstrated that statins therapy as well as angiotensin converting enzyme inhibitors is associated with improvements in endothelial function in diabetes. Although antioxidants provide short-term improvement of endothelial function in humans, all studies of the effectiveness of preventive antioxidant therapy have been disappointing. Control of hyperglycemia thus remains the best way to improve endothelial function and to prevent atherosclerosis and other cardiovascular complications of diabetes. In the present review we provide the up to date details on this subject.

Figures

Figure 1
Figure 1
Progression of endothelial dysfunction in relation the progression of insulin resistance (Hsueh et al 2004).
Figure 2
Figure 2
Pathophysiology of hyperglycemia induced endothelial dysfunction (DeVriese et al 2000).

References

    1. Aanderud S, Krane H, Nordoy A. Influence of glucose, insulin and sera from diabetic patients on the prostacyclin synthesis in vitro in cultured human endothelial cells. Diabetologia. 1985;28:641–4.
    1. Al Suwaidi J, Higano ST, Holmes DR, et al. Obesity is an independent predictor of coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol. 2001;37:1523.
    1. Ametov AS, Demidova TIu, Kosykh SA. NO synthesis in the vascular endothelium of patients with type II diabetes. Klin Med (Mosk) 2005;83(8):62–8.
    1. Ammar RF, Jr, Gutterman DD, Brooks LA, et al. Free radicals mediate endothelial dysfunction of coronary arterioles in diabetes. Cardiovasc Res. 2000;47:595–601.
    1. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol. 1999;34:631–8.
    1. Anderson TJ, Elstein E, Haber H, et al. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study) J Am Coll Cardiol. 2000;35:60–6.
    1. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995;26:1235–41.
    1. Ang C, Hillier C, Johnston F, et al. Endothelial function is preserved in pregnant women with well-controlled type 1 diabetes. BJOG. 2002;109:699–707.
    1. Ansell BJ, Watson KE, Weiss RE, et al. hsCRP and HDL Effects of Statins Trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels. A clinical investigation. Heart Dis. 2003;5:2–7.
    1. Arbogast BW, Lee GM, Raymond TL. In vitro injury of porcine aortic endothelial cells by very-low-density lipoproteins from diabetic rat serum. Diabetes. 1982;31:593–9.
    1. Arcaro G, Cretti A, Balzano S, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation. 2002;105:576–82.
    1. Arcaro G, Zenere BM, Saggiani F, et al. ACE inhibitors improve endothelial function in type 1 diabetic patients with normal arterial pressure and microalbuminuria. Diabetes Care. 1999;22:1536–42.
    1. Arner P. The adipocyte in insulin resistance: key molecules and impact of the thiazolidinediones. Trends Endocrinol Metab. 2003;14:137–45.
    1. Avena R, Mitchell ME, Nylen ES, et al. Insulinaction enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J VascSurg. 1998;28:1024–32.
    1. Avogaro A, Calo L, Piarulli F, et al. Effect of acute ketosis on the endothelial function of type 1 diabetic patients: the role of nitric oxide. Diabetes. 1999;48:391–7.
    1. Avogaro A, Fadini GP, Gallo A, et al. Endothelial dysfunction in type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2006;16(Suppl 1):S39–45.
    1. Avogaro A, Miola M, Favaro A, et al. Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. Eur J Clin Invest. 2001;31:603–9.
    1. Bagi Z, Koller A, Kaley G. Peroxisome proliferator-activated receptor activation increases NO bioavailability in coronary arterioles in type 2 diabetes by reducing oxidative stress. Am J Physiol HeartCirc Physiol. 2004;286:H742–8.
    1. Balletshofer BM, Rittig K, Enderle MD, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation. 2000;101:1780–4.
    1. Basta G, Del Turco S, De Caterina R. Advanced glycation endproducts: implications for accelerated atherosclerosis in diabetes. Recenti Prog Med. 2004;95:67–80.
    1. Beishuizen ED, Tamsma JT, Jukema JW, et al. The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease. Diabetes Care. 2005;28:1668–74.
    1. Bengel FM, Abletshauser C, Neverve J, et al. Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus – a randomized study using positron emission tomography. Diabet Med. 2005;22:158–63.
    1. Bhargava K, Hansa G, Bansal M, et al. Endothelium-dependent brachial artery flow mediated vasodilatation in patients with diabetes mellitus with and without coronary artery disease. J Assoc Physicians India. 2003;51:355–8.
    1. Biegelsen ES, Loscalzo J. Endothelial function and atherosclerosis. Coron Artery Dis. 1999;10:241–56.
    1. Bijlstra PJ, Smits P, Lutterman JA, et al. Effect of long-term angiotensin-converting enzyme inhibition on endothelial function in patients with the insulin-resistance syndrome. J Cardiovasc Pharmacol. 1995;25:658–64.
    1. Bilsborough W, O’Driscoll G, Stanton K, et al. Effect of lowering tumour necrosis factor-alpha on vascular endothelial function in Type II diabetes. Clin Sci (Lond) 2002;103:163–9.
    1. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol. 2000;129:823–34.
    1. Blair A, Shaul PW, Yuhanna IS, et al. Oxidized low-density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem. 1999;274:32512–19.
    1. Bloomgarden ZT. Endothelial dysfunction, neuropathy and the diabetic foot, diabetic mastopathy, and erectile dysfunction. Diabetes Care. 1998;21:183–9.
    1. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta celldysfunction. Eur J Clin Invest. 2002;32(Suppl 3):14–23.
    1. Bonner G. Hyperinsulinemia, insulin resistance, and hypertension. J Cardiovasc Pharmacol. 1994;24(Suppl 2):S39–49.
    1. Booth G, Stalker TJ, Lefer AM, et al. Mechanisms of amelioration of glucose-induced endothelial dysfunction following inhibition of protein kinase C in vivo. Diabetes. 2002;51:1556–64.
    1. Briner VA, Luscher TF. Role of vascular endothelial abnormalities in clinical medicine: atherosclerosis, hypertension, diabetes, and endotoxemia. Adv Intern Med. 1994;39:1–22.
    1. Busse R, Fleming I, Hecker M. Signal transduction in endothelium-dependent vasodilatation. Eur Heart J. 1993;14(Suppl I):2–9.
    1. Caballero AE, Arora S, Saouaf R, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes. 1999;48:1856–62.
    1. Caballero AE, Saouaf R, Lim SC, et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism. 2003;52:173–80.
    1. Cacoub P, Carayon A, Dorent R, et al. Endothelin: the vasoconstrictor of the 1990’s? Rev Med Interne. 1993;14:229–32.
    1. Calles-Escandon J, Ballor D, Harvey-Berino J, et al. Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction. Am J Clin Nutr. 1996;64:7–11.
    1. Cardillo C, Campia U, Bryant MB, et al. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation. 2002;106:1783–7.
    1. Ceriello A, Cavarape A, Martinelli L, et al. The post-prandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med. 2004;21:171–5.
    1. Chan JR, Boger RH, Bode-Boger SM, et al. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol. 2000;20:1040–6.
    1. Chappey O, Wautier MP, Boval B, et al. Endothelial cells in culture: an experimental model for the study of vascular dysfunctions. Cell Biol Toxicol. 1996;12:199–205.
    1. Charvat J, Michalova K, Chlumsky J, et al. The association between left ventricle diastolic dysfunction and endothelial dysfunction and the results of stress myocardial SPECT in asymptomatic patients with type 2 diabetes. J Int Med Res. 2005;33:473–82.
    1. Chaturvedi N, Fuller JH, Pokras F, et al. Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition. Diabet Med. 2001;18:288–94.
    1. Cheetham C, O’Driscoll G, Stanton K, et al. Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes. Clin Sci (Lond) 2001;100:13–17.
    1. Cheethams C, Collis J, O’Driscoll G, et al. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J Am Coll Cardiol. 2000;36:1461–6.
    1. Chen X-L, Tummala PE, Olbrych MT, et al. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res. 1998;83:952–9.
    1. Chiarelli F, Pomilio M, Mohn A, et al. Homocysteine levels during fasting and after methionine loading in adolescents with diabetic retinopathy and nephropathy. J Pediatr. 2000;137:386–92.
    1. Chico A, Perez A, Cordoba A, et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia. 1998;41:684–93.
    1. Chowienczyk PJ, Brett SE, Gopaul NK, et al. Oral treatment with an antioxidant (raxofelast) reduces oxidative stress and improves endothelial function in men with type II diabetes. Diabetologia. 2000;43:974–7.
    1. Cipolla MJ. Elevated glucose potentiates contraction of isolated rat resistance arteries and augments protein kinase C-induced intracellular calcium release. Metabolism. 1999;48:1015–22.
    1. Clarkson P, Celermajer DS, Donald AE, et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol. 1996;28:573–9.
    1. Cleland SJ, Petrie JR, Small M, et al. Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension. 2000;35(1 Pt 2):507–11.
    1. Clemens A, Klevesath MS, Hofmann M, et al. Octreotide (somatostatin analog) treatment reduces endothelial cell dysfunction in patients with diabetes mellitus. Metabolism. 1999;48:1236–40.
    1. Conger JD. Endothelial regulation of vascular tone. Hosp Pract. 1994;29:117–26. (Off Ed)
    1. Contreras F. Diabetes and hypertension physiopathology and therapeutics. J Hum Hypertens. 2000;14:S26–31.
    1. Costa A, Casamitjana R, Casals E, et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet Med. 2003;20:743–5.
    1. Costacou T, Lopes-Virella MF, Zgibor JC, et al. Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. J Diabetes Complications. 2005;19:183–93.
    1. Cotellessa M, Minniti G, Cerone R, et al. Low total plasma homocysteine concentrations in patients with type 1 diabetes. Diabetes Care. 2001;24:969–71.
    1. Cowan DB, Langille BL. Cellular and molecular biology of vascular remodeling. Curr Opin Lipidol. 1996;7:94–100.
    1. Cronin CC, McPartlin JM, Barry DG, et al. Plasma homocysteine concentrations in patients with type 1 diabetes. Diabetes Care. 1998;21:1843–7.
    1. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.
    1. Dalla Nora E, Passaro A, Zamboni PF, et al. Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study. J Endocrinol Invest. 2003;26:73–8.
    1. Dandona P, Aljada A. Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents. J Diabetes Complications. 2004;18:91–102.
    1. Darko D, Dornhorst A, Kelly FJ, et al. Lack of effect of oral vitamin C on blood pressure, oxidative stress and endothelial function in Type II diabetes. Clin Sci (Lond) 2002;103:339–44.
    1. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med. 1999;16:179–92.
    1. De Cobelli F, Fiorina P, Perseghin G, et al. L-arginine-induced vasodilation of the renal vasculature is preserved in uremic type 1 diabetic patients after kidney and pancreas but not after kidney-alone transplantation. Diabetes Care. 2004;27:947–54.
    1. De Mattia G, Bravi MC, Laurenti O, et al. Reduction of oxidative stress by oral N-acetyl-L-cysteine treatment decreases plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non-dyslipidaemic, normotensive, patients with non-insulin-dependent diabetes. Diabetologia. 1998;41:1392–6.
    1. De Mattia G, Laurenti O, Fava D. Diabetic endothelial dysfunction: effect of free radical scavenging in Type 2 diabetic patients. J Diabetes Complication. 2003;17(2 Suppl):30–5.
    1. De Meyer GR, Herman AG. Vascular endothelial dysfunction. Prog Cardiovasc Dis. 1997;39:325–42.
    1. De Vriese AS, Verbeuren TJ, de Voorde JV, et al. Endothelial dysfunction in diabetes. British Journal of Pharmacology. 2000;130:963–74.
    1. Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: A statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23:7–17.
    1. Dhein S, Kabat A, Olbrich A, et al. Effect of chronic treatment with vitamin E on endothelial dysfunction in a type I in vivo diabetes mellitus model and in vitro. J Pharmacol Exp Ther. 2003;305:114–22.
    1. Dogra G, Rich L, Stanton K, et al. Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria. Diabetologia. 2001;44:593–601.
    1. Dosquet C, Wautier MP, Guillausseau PJ, et al. Monokines and endothelial cell proliferation in patients with diabetes mellitus. Diabete Metab. 1994;20:37–42.
    1. Drab M, Verkade P, Elger M. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001;293:2449–52.
    1. Duka I, Shenouda S, Johns C, et al. Role of the B(2) receptor of bradykinin in insulin sensitivity. Hypertension. 2001;38:1355–60.
    1. Dumont AS, Hyndman ME, Dumont RJ, et al. Improvement of endothelial function in insulin-resistant carotid arteries treated with pravastatin. J Neurosurg. 2001;95:466–71.
    1. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37:1047–52.
    1. Elliot TG, Cockcroft JR, Groop PH, et al. Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependentdiabetic patients: blunted vasosonstriction on patients with microalbuminuria. Clin Sci (Lond) 1993;85:687–93.
    1. Evans M, Anderson RA, Graham J, et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation. 2000;101:1773–9.
    1. Evans M, Anderson RA, Smith JC, et al. Effects of insulin lispro and chronic vitamin C therapy on postprandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes mellitus. Eur J Clin Invest. 2003;33:231–8.
    1. Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol. 2000;68:437–46.
    1. Farhangkhoee H, Khan ZA, Kaur H, et al. Vascular endothelial dysfunction in diabetic cardiomyopathy: Pathogenesis and potential treatment targets. Pharmacol Ther. 2006;111:384–99.
    1. Farouque HM, Meredith IT. The assessment of endothelial function in humans. Coron Artery Dis. 2001;12:445–54.
    1. Fasching P, Veitl M, Rohac M, et al. Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1996;81:4313–17.
    1. Fegan PG, Shore AC, Mawson D, et al. Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy. Diabet Med. 2005;22:1670–6.
    1. Forst T, Lubben G, Hohberg C, et al. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation. 2005;12:543–50.
    1. Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol. 2002;90:947–52.
    1. Fuchsjager-Mayrl G, Pleiner J, Wiesinger GF, et al. Exercise training improves vascular endothelial function in patients with type 1 diabetes. Diabetes Care. 2002;25:1795–801.
    1. Gaboury CL, Simonson DC, Seely EW, et al. Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension. J Clin Invest. 1994;94:2295–300.
    1. Gaenzer H, Neumayr G, Marschang P, et al. Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes mellitus. Am J Cardiol. 2002;89:431–4.
    1. Garcia Soriano F, Virag L, Jagtap P, et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med. 2001;7:108–13.
    1. Gasic S, Wagner OF, Fasching P, et al. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am J Hypertens. 1999;12(2 Pt 1):217–22.
    1. Gazis A, White DJ, Page SR, et al. Effect of oral vitamin E (α-tocopherol) supplementation on vascular endothelial function in type 2 diabetes mellitus. Diabet Med. 1999;16:304–11.
    1. Glowinska B, Urban M, Peczynska J, et al. Selected adhesion molecules: sICAM-1 and sVCAM-1 as markers of endothelial dysfunction in diabetic children and adolescence. Pol Merkuriusz Lek. 2003;14:205–9.
    1. Goldin E, Casadevall M, Mourelle M, et al. Role of prostaglandins and nitric oxide in gastrointestinal hyperemia of diabetic rats. Am J Physiol. 1996;270:G684–90.
    1. Goran MI, Ball GD, Cruz ML. Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. J Clin Endocrinol Metab. 2003;88:1417–27.
    1. Haefliger IO, Flammer J, Luscher TF. Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. Invest Ophthalmol Vis Sci. 1992;33:2340–3.
    1. Hadi ARH, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy and outcome. Vascular Health and Risk Management. 2005;1:183–98.
    1. Haffner SM. Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clinc Pract. 2003;61(Suppl 1):S9–18.
    1. Haller H. Endothelial function. General considerations. Drugs. 1997;53(Suppl 1):1–10.
    1. Hattori Y, Kasai K, Nakamura T, et al. Effect of glucose and insulin on immunoreactive endothelin-1 release from cultured porcine aortic endothelial cells. Metabolism. 1991;40:165–9.
    1. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev. 2002;18(Suppl 2):S10–15.
    1. Hauner H, Takahashi M, Funahashi T, et al. PPAR_ ligands increase expression and plasma concentrations of adiponectin, an adipose derived protein. Diabetes. 2001;50:2094–9.
    1. Hazel L, Kenneth A, Roebuck O. Oxidant stress and endothelial cell dysfunction. Am J Physiol Cell Physio. 2001;280:C719–41.
    1. Hedner T, Sun X. Measures of endothelial function as an endpoint in hypertension? Blood Press Suppl. 1997;2:58–66.
    1. Henry RM, Ferreira I, Kostense PJ, et al. Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolismis not; The Hoorn Study. Atherosclerosis. 2004;174:49–56.
    1. Hermann TS, Li W, Dominguez H, et al. Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91:1001–8.
    1. Hink U, Tsilimingas N, Wendt M, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus: therapeutic implications. Endocrinol. 2003;2:293–304.
    1. Hofmann MA, Kohl B, Zumbach MS, et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care. 1998;21:841–8.
    1. Honisett SY, Stojanovska L, Sudhir K, et al. Hormone therapy impairs endothelial function in postmenopausal women with type 2 diabetes mellitus treated with rosiglitazone. J Clin Endocrinol Metab. 2004;89:4615–9.
    1. Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation. 2001;103:799–805.
    1. Hsueh WA, Anderson PW. Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus [clinical conference] Hypertension. 1992;20:253–63.
    1. Hsueh WA, Anderson PW. Systemic hypertension and the renin-angiotensin system in diabetic vascular complications. Am J Cardiol. 1993;72:14H–21H.
    1. Hsueh A, Lyon J, Manuel J, et al. Insulin resistance and the endothelium. Am J Med. 2004;117:109–17.
    1. Hubacek J, Verma S, Shewchuk L, et al. Rationale and design of the Glitazones and the Endothelium (GATE) study: evaluation of rosiglitazone on endothelial function in patients with diabetes. Can J Cardiol. 2004;20:1449–53.
    1. Hultberg B, Agardh E, Andersson A, et al. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest. 1991;51:277–82.
    1. Huvers FC, De Leeuw PW, Houben AJ, et al. Endothelium-dependent vasodilatation, plasma markers of endothelial function, and adrenergic vasoconstrictor responses in type 1 diabetes under near-normoglycemic conditions. Diabetes. 1999;48:1300–7.
    1. Janka HU. Platelet and endothelial function tests during metformin treatment in diabetes mellitus. Horm Metab Res Suppl. 1985;15:120–2.
    1. Jarvisalo MJ, Raitakari M, Toikka JO, et al. Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. Circulation. 2004;109:1750–5.
    1. Jensen S. Microalbuminuria and risk of atherosclerosis. Clinical epidemiological and physiological investigators. Dan Med Bull. 2000;47:63–78.
    1. Johnstone MT, Creager SJ, Scales KM, et al. impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 1993;88:2510–16.
    1. Jorge C-E, Marilyn C. Diabetes and endothelial dysfunction: a clinical perspective. Endocrine Reviews. 2001;22:36–52.
    1. Joyce M, Moore K, Thompson C, et al. Hydroxy-methylglutaryl-coenzyme A reductase inhibition improves endothelial dysfunction in type-1 diabetes. Eur J Vasc Endovasc Surg. 2004;27:432–7.
    1. Kabat A, Dhein S. L-arginine supplementation prevents the development of endothelial dysfunction in hyperglycaemia. Pharmacology. 2006;76:185–91.
    1. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473–81.
    1. Kamide K, Nagano M, Nakano N, et al. Insulin resistance and cardiovascular complications in patients with essential hypertension. Am J Hypertens. 1996;9:1165–71.
    1. Katakam PV, Ujhelyi MR, Hoenig M, et al. Metformin improves vascular function in insulin-resistant rats. Hypertension. 2000;35(1 Pt 1):108–12.
    1. Keech A, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003;26:2713–21.
    1. Khder Y, Briancon S, Petermann R, et al. Shear stress abnormalities contribute to endothelial dysfunction in hypertension but not in type II diabetes. J Hypertens. 1998;16:1619–25.
    1. Kim SH, Park KW, Kim YS, et al. Effects of acute hyperglycemia on endothelium-dependent vasodilation in patients with diabetes mellitus or impaired glucose metabolism. Endothelium. 2003;10:65–70.
    1. Kim Y-B, Ciaraldi TP, Kong A, et al. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110_ protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes. 2002;51:443–8.
    1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates and projections. Diabetes Care. 1998;21:1414–31.
    1. Kita T, Kume N, Minami M, et al. Role of oxidized LDL in atherosclerosis. Ann NY Acad Scie. 2001;947:199–206.
    1. Koh MS, Majewski BB, Rhodes EL. Diabetic serum stimulates the proliferation of endothelial cells in culture. Diabetes Res. 1985;2:287–9.
    1. Konukoglu D, Dogan E, Turhan MS, et al. Impaired glucose tolerance: its relevance to early endothelial dysfunction. Horm Metab Res. 2003;35:607–10.
    1. Kruszynska YT, Yu JG, Olefsky JM, et al. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes. 2000;49:633–9.
    1. Kuboki K, Jiang ZY, Takahara N, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation. 2000;101:676–81.
    1. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med. 1990;227:273–8.
    1. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86:280–8.
    1. Leinonen E, Hurt-Camejo E, Wiklund O, et al. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis. 2003;166:387–94.
    1. Lemne C, de Faire U. Elevation of plasminogen activator inhibitor 1 in borderline hypertension is linked to concomitant metabolic disturbances. Eur J Clin Invest. 1996;26:692–7.
    1. Leurs PB, Stolk RP, Hamulyak K, et al. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care. 2002;25:1340–5.
    1. Levin ER. Endothelins as cardiovascular peptides. AmJ Nephrol. 1996;16:246–51.
    1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–74.
    1. Lim AC, et al. Vasculopathy in type 2 diabetic individuals without microalbumuria. Diabetes Care. 1999;22:1865–70.
    1. Loomans CJ, de Koning EJ, Staal FJ, et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes. 2004;53:195–9.
    1. Lorenzi M, Montisano DF, Toledo S, et al. High glucose induces DNA damage in cultured human endothelial cells. J Clin Invest. 1986;77:322–5.
    1. Loviscach M, Rehman N, Carter L, et al. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabetologia. 2000;43:304–11.
    1. Luscher TF. The endothelium. Target and promoter of hypertension? Hypertension. 1990;15:482–5.
    1. Luscher TF, Tanner FC, Tschudi MR, et al. Endothelial dysfunction in coronary artery disease. Annu Rev Med. 1993;44:395–418.
    1. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144:2195–200.
    1. MacKenzie KE, Wiltshire EJ, Gent R, et al. Folate and vitamin B6 rapidly normalize endothelial dysfunction in children with type 1 diabetes mellitus. Pediatrics. 2006;118:242–53.
    1. Maejima K, Nakano S, Himeno M, et al. Increased basal levels of plasma nitric oxide in Type 2 diabetic subjects. Relationship to microvascular complications. J Diabetes Complications. 2001;15:135–43.
    1. Maiorana A, O’Driscoll G, Cheetham C, et al. The effect of combined aerobic and resistance exercise training on vascular function in type 2 diabetes. J Am Coll Cardiol. 2001;38:860–6.
    1. Makimattila S, Virkamaki A, Groop PH, et al. Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. Circulation. 1996;94:1276–82.
    1. Makino N, Maeda T, Sugano M, et al. High serum TNF-alpha level in Type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells. J Diabetes Complications. 2005;19:347–55.
    1. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation. 1996;94:258–65.
    1. Manzella D, Grella R, Abbatecola AM, et al. Repaglinide administration improves brachial reactivity in type 2 diabetic patients. Diabetes Care. 2005;28:366–71.
    1. Manzella D, Ragno E, Abbatecola AM, et al. Residual C-peptide secretion and endothelial function in patients with Type II diabetes. Clin Sci (Lond) 2003;105:113–18.
    1. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001;37:1344–50.
    1. Matsuoka H. Endothelial dysfunction associated with oxidative stress in human. Diabetes Res Clin Practice. 2001;54(Suppl):S65–72.
    1. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovasculardisease. Am J Cardiol. 2003;91:30H–37H.
    1. McFarlane R, McCredie RJ, Bonney MA, et al. Angiotensin converting enzyme inhibition and arterial endothelial function in adults with type 1 diabetes mellitus. Diabet Med. 1999;16:62–6.
    1. McIntyre M, Bohr DF, Dominiczak AF. Endothelial function hypertension: the role of superoxide anion. Hypertension. 1999;34:539–45.
    1. McSorley PT, Bell PM, Young IS, et al. Endothelial function, insulin action and cardiovascular risk factors in young healthy adult offspring of parents with Type 2 diabetes: effect of vitamin E in a randomized double-blind, controlled clinical trial. Diabet Med. 2005;22:703–10.
    1. McVeigh GE, Cohn JN. Endothelial dysfunction and the metabolic syndrome. Curr Diab Rep. 2003;3:87–92.
    1. Meeking DR, Cummings MH, Thorne S, et al. Endothelial dysfunction in Type 2 diabetic subjects with and without microalbuminuria. Diabet Med. 1999;16:841–7.
    1. Meigs JB, Hu FB, Rifai N, et al. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA. 2004;291:1978–86.
    1. Moldoveanu E, Tanaseanu C, Tanaseanu S, et al. Plasma markers of endothelial dysfunction in type 2 diabetics. Eur J Intern Med. 2006;17:38–42.
    1. Mombouli JV. ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide. Drugs. 1997;54(Suppl 5):12–22.
    1. Mombouli JV, Vanhoutte PM. Kinins and endothelial control of vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1995;35:679–705.
    1. Moussavi N, Renier G, Roussin A, et al. Lack of concordance between plasma markers of cardiovascular risk and intima-media thickness in patients with type 2 diabetes. Diabetes Obes Metab. 2004;6:69–77.
    1. Mudaliar S, Henry RR. New oral therapies for type 2 diabetesmellitus: the glitazones or insulin sensitizers. Annu Rev Med. 2001;52:239–57.
    1. Mullen MJ, Clarkson R, Donald AE, et al. Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: A randomized, double blind study. J Am Coll Cardiol. 1998;31:1330–5.
    1. Myrup B, Mathiesen ER, Ronn B, et al. Endothelial function and serum lipids in the course of developing microalbuminuria in insulin-dependent diabetes mellitus. Diabetes Res. 1994;26:33–9.
    1. Neri S, Bruno CM, Leotta C, et al. Early endothelial alterations in non-insulin-dependent diabetes mellitus. Int J Clin Lab Res. 1998;28:100–3.
    1. Nielsen FS, Rossing P, Gall MA, et al. Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy. Scand J Clin Lab Invest. 1997;57:427–34.
    1. Nordt TK, Klassen KJ, Schneider DJ, et al. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb. 1993;13:1822–8.
    1. Nystrom T, Nygren A, Sjoholm A. Persistent endothelial dysfunction is related to elevated C-reactive protein (CRP) levels in Type II diabetic patients after acute myocardial infarction. Clin Sci (Lond) 2005;108:121–8.
    1. O’Driscoll G, Green D, Maiorana A, et al. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1999;33:1506–11.
    1. O’Driscoll G, Green D, Rankin J, et al. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest. 1997;100:678–84.
    1. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126–31.
    1. Okon EB, Chung AW, Rauniyar P. Compromised arterial function in human type 2 diabetic patients. Diabetes. 2005;54:2415–23.
    1. Okouchi M, Okayama N, Imai S, et al. High insulin enhances neutrophil transendothelial migration through increasing surface expression of platelet endothelial cell adhesion molecule-1 via activation of mitogen activated protein kinase. Diabetologia. 2002;45:1449–56.
    1. Omori H, Nagashima H, Tsurumi Y, et al. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol. 2002;54:395–9.
    1. Oomen PH, Kant GD, Dullaart RP, et al. Acute hyperglycemia and hyperinsulinemia enhance vasodilatation in Type 1 diabetes mellitus without increasing capillary permeability and inducing endothelial dysfunction. Microvasc Res. 2002;63:1–9.
    1. Oomen PH, Kant GD, Dullaart RP, et al. No effects of acute hyperglycaemia and hyperinsulinaemia on skin microcirculation and endothelial markers in Type II diabetes mellitus. Scand J Clin Lab Invest. 2004;64:119–27.
    1. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000;102:1296–301.
    1. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103:1057–63.
    1. Ouvina SM, La Greca RD, Zanaro NL, et al. Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients. Thromb Res. 2001;102:107–14.
    1. Paniagua JA, Lopez-Miranda J, Escribano A, et al. Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes. Diabetes. 2002;51:2596–603.
    1. Paolisso G, Giugliano D. Oxidative stress and insulin action: is there a relationship? Diabetologia. 1996;39:357–63.
    1. Pavia C, Ferrer I, Valls C, et al. Total homo-cysteine in patients with type 1 diabetes. Diabetes Care. 2000;23:84–7.
    1. Pena AS, Wiltshire E, Gent R, et al. Folic acid improves endothelial function in children and adolescents with type 1 diabetes. J Pediatr. 2004;144:500–4.
    1. Perticone F, Ceravolo R, Candigliota M, et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes. 2001;50:159–65.
    1. Pieper GM, Jordan M, Adams MB, et al. Restoration of vascular endothelial function in diabetes. Diabetes Res Clin Pract. 1996;31(Suppl):S157–62.
    1. Pieper GM, Jordan M, Adams MB, et al. Syngeneic pancreatic islet transplantation reverses endothelial dysfunction in experimental diabetes. Diabetes. 1995;44:1106–13.
    1. Pieper GM, Langenstroer P, Siebeneich W. Diabetic-induced endothelial dysfunction in rat aorta: role of hydroxyl radicals. Cardiovasc Res. 1997;34:145–56.
    1. Pieper GM, Siebeneich W. Diabetes-induced endothelial dysfunction is prevented by long-term treatment with the modified iron chelator, hydroxyethyl starch conjugated-deferoxamine. J Cardiovasc Pharmacol. 1997;30:734–8.
    1. Pieper GM, Siebeneich W. Temocapril, an angiotensin converting enzyme inhibitor, protects against diabetes-induced endothelial dysfunction. Eur J Pharmacol. 2000;403:129–32.
    1. Pinkney JH, Downs L, Hopton M, et al. Endothelial dysfunction in Type 1 diabetes mellitus: relationship with LDL oxidation and the effects of vitamin E. Diabet Med. 1999;16:993–9.
    1. Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabete. 2005;54:2206–11.
    1. Pistrosch F, Passauer J, Fischer S, et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care. 2004;27:484–90.
    1. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol. 2001;88:10–15.
    1. Prasad A, Tupas-Habib T, Schenke WH, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation. 2000;101:2349–54.
    1. Prior JO, Quinones MJ, Hernandez-Pampaloni M, et al. Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation. 2005;111:2291–8.
    1. Qian LB, Wang HP, Qiu WL, et al. Interleukin-2 protects against endothelial dysfunction induced by high glucose levels in rats. Vascul Pharmacol. 2006;45:374–82.
    1. QuinÜones MJ, Hernandez-Pampaloni M, Chon Y, et al. Improvement of coronary artery endothelial dysfunction in insulin resistant patients after treatment with insulin-sensitizing thiazolidinediones. Diabetes. 2002;51:A172.
    1. Rabelink TJ, Bakris GL. The renin-angiotensin system in diabetic nephropathy: the endothelial connection. Miner Electrolyte Metab. 1998;24:381–8.
    1. Ramsay JE, Simms RJ, Ferrell WR, et al. Enhancement of endothelial function by pregnancy: inadequate response in women with type 1 diabetes. Diabetes Care. 2003;26:475–9.
    1. Rask-Madsen N, Ihlemann T, Krarup E, et al. Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes. 2001;50:2611–18.
    1. Regensteiner JG, Popylisen S, Bauer TA, et al. Oral L-arginine and vitamins E and C improve endothelial function in women with type 2 diabetes. Vasc Med. 2003;8:169–75.
    1. Rizzo V, McIntosh DP, Oh P, et al. In situ flow activates endothelial nitric oxide synthase in luminal caveolae of endothelium with rapid caveolin dissociation and calmodulin association. J Biol Chem. 1998;273:34724–9.
    1. Robillon J, Canivet B, Candito M, et al. Type 1 diabetes mellitus and homocyst(e)ine. Diabetes Metab. 1994;20:494–6.
    1. Sahach VF, Prysiazhna OD, Tkachenko MN, et al. Effect of L-arginine on the endothelium functional activity in experimental diabetes mellitus. Fiziol Zh. 2005;51:3–7.
    1. Salmi M, Stolen C, Jousilahti P, et al. Insulin-regulated increase of soluble vascular adhesion protein-1 in diabetes. Am J Pathol. 2002;161:2255–62.
    1. Sato N, Kase H, Kato T. Effect of angiotensin II type 1 receptor antagonist on oxidative stress markers in type 2 diabetic patients with hypertension. Nippon Rinsho. 2003;61:1245–9.
    1. Schneider JG, Tilly N, Hierl T, et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens. 2002;15:967–72.
    1. Shemyakin A, Bohm F, Wagner H, et al. Enhanced endothelium-dependent vasodilatation by dual endothelin receptor blockade in individuals with insulin resistance. J Cardiovasc Pharmacol. 2006;47:385–90.
    1. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–7.
    1. Shestakova MV, Iarek-Martynov IR, Ivanishina NS, et al. Assessment of vasomotor endothelial function in patients with diabetes mellitus type 1 at different stages of diabetic nephropathy. Ter Arkh. 2003;75:17–21.
    1. Shestakova MV, Iarek-Martynova IR, Ivanishina NS, et al. Cardiorenal syndrome in type 1 diabetes mellitus: the role of endothelial dysfunction. Kardiologiia. 2005a;45:35–41.
    1. Shestakova MV, Jarek-Martynowa IR, Ivanishina NS, et al. Role of endothelial dysfunction in the development of cardiorenal syndrome in patients with type 1 Diabetes. Res Clin Pract. 2005b;68(Suppl 1):S65–72.
    1. Skrha J, Vackova I, Kvasnicka J, et al. Plasma-free N-terminal fibronectin 30-kDa domain as a marker of endothelial dysfunction in type 1 diabetes mellitus. Eur J Clin Invest. 1990;20:171–6.
    1. Skyrme-Jones RA, Meredith IT. Soluble adhesion molecules, endothelial function and vitamin E in type 1 diabetes. Coron Artery Dis. 2001;12:69–75.
    1. Skyrme-Jones RA, O’Brien RC, Luo M, et al. Endothelial vasodilator function is related to low-density lipoprotein particle size and low-density lipoprotein vitamin E content in type 1 diabetes. J Am Coll Cardiol. 2000;35:292–9.
    1. Sourij H, Zweiker R, Wascher TC. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care. 2006;29:1039–45.
    1. Stalker TJ, Skvarka CB, Scalia R. A novel role for calpains in the endothelial dysfunction of hyperglycemia. FASEB J. 2003;17:1511–13.
    1. Stehouwer CD, Fischer HR, van Kuijk AW, et al. Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes. 1995;44:561–4.
    1. Steinberg HO, Brechtel G, Johnson A, et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest. 1994;94:1172–9.
    1. Steinberg HO, Chaker H, Leaming R, et al. Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest. 1996;97:2601–10.
    1. Steinberg HO, Tarshoby M, Monestel R, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest. 1997;100:1230–9.
    1. Studdy PR, Lapworth R, Bird R. Angiotensin-converting enzyme and its clinical significance-a review. J Clin Pathol. 1983;36:938–47.
    1. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002;287:1420–6.
    1. Tamai O, Matsuoka H, Itabe H, et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 1997;95:76–82.
    1. Tan KC, Chow WS, Ai VH, et al. Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion intype 2 diabetic patients with microalbuminuria. Diabetes Metab Res Rev. 2002;18:71–6.
    1. Tan KC, Chow WS, Tam SC, et al. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2002;87:563–8.
    1. Targher G, Bertolini L, Zenari L, et al. Cigarette smoking and plasma total homocysteine levels in young adults with type 1 diabetes. Diabetes Care. 2000;23:524–8.
    1. Tarnow L, Hovind P, Teerlink T. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care. 2004 Mar;27(3):765–9.
    1. Taddei S, Virdis A, Ghiadoni L, et al. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs. 2002;62:265–84.
    1. Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase. J Clin Invest. 1991;87:1643–8.
    1. Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol. 1992;263(2 Pt 2):H321–6.
    1. Thompson GR, Maher VM, Matthews S, et al. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-densitylipoprotein apheresis. Lance. 1995;345:811–16.
    1. Thorand B, Baumert J, Chambless L, et al. MONICA/KORA Study Group. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Bio. 2006;26:398–405.
    1. Toikka JO, Ahotupa M, Viikari JSA, et al. Constantly low HDLcholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis. 1999;147:133–8.
    1. Toop MJ, Dallinger KJ, Jennings PE, et al. Angiotensin-converting enzyme (ACE): relationship to insulin-dependent diabetes and microangiopathy. Diabet Med. 1986;3:455–7.
    1. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17:1121–7.
    1. Tsukahara H, Sekine K, Uchiyama M, et al. Formation of advanced glycosylation end products and oxidative stress in young patients with type 1 diabetes. Pediatr Res. 2003;54:419–24.
    1. Tsunekawa T, Hayashi T, Kano H, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation. 2001;104:376–9.
    1. Tsunekawa T, Hayashi T, Kano H, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation. 2001;104:376–9.
    1. Tummala PE, Chen X-L, Sundell CL. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the reninangiotensin system and atherosclerosis. Circulation. 1999;100:1223–9.
    1. Uittenbogaard A, Shaul PW, Yuhanna IS, et al. High-density lipoprotein prevents oxidized low-density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem. 2000;275:11278–83.
    1. Vaccaro O, Perna AF, Mancini FP, et al. Plasma homocysteine and microvascular complications in type 1 diabetes. Nutr Metab Cardiovasc Dis. 2000;10:297–304.
    1. Van de Ree MA, Huisman MV, De Man FH, et al. Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc Res. 2001;52:299–305.
    1. Van Etten RW, de Koning EJ, Honing ML, et al. Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol. 2002;22:799–804.
    1. Van Venrooij FV, van de Ree MA, Bots ML, et al. Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care. 2002;25:1211–16.
    1. Vehkavaara S, Makimattila S, Schlenzka A, et al. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2000;20:545–50.
    1. Vehkavaara S, Yki-Jarvinen H. 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2004;24:325–30.
    1. Verrotti A, Greco R, Basciani F, et al. von Willebrand factor and its propeptide in children with diabetes. Relation between endothelial dysfunction and microalbuminuria. Pediatr Res. 2003;53:382–6.
    1. Viberti GC, Benigni A, Bognetti E, et al. Glomerular hyperfiltration and urinary prostaglandins in type 1 diabetes mellitus. Diabet Med. 1989;6:219–23.
    1. Wakino S, Law RE, Hsueh WA. Vascular protective effects by activation of nuclear receptor PPAR. J Diabetes Complications. 2002;16:46–9.
    1. Watanabe Y, Sunayama S, Shimada K, et al. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thromb. 2000;7:159–63.
    1. Watts GF, Playford DA. Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: a hypothesis. Atherosclerosis. 1998;141:17–30.
    1. Wautier JL, Setiadi H, Vilette D, et al. Leukocyte adhesion to endothelial cells. Biorheology. 1990;27:425–32.
    1. Wautier JL, Wautier MP, Pintigny D, et al. Factors involved in cell adhesion to vascular endothelium. Blood Cells. 1983;9:221–34.
    1. Wautier JL, Zoukourian C, Chappey O, et al. Receptor mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest. 1996;97:238–43.
    1. Wen Y, Skidmore JC, Porter-Turner MM, et al. Relationship of glycation, antioxidant status and oxidative stress to vascular endothelial damage in diabetes. Diabetes Obes Metab. 2002;4:305–8.
    1. Williams B. A potential role for angiotensin II-induced vascular endothelial growth factor expression in the pathogenesis of diabetic nephropathy? Miner Electrolyte Metab. 1998;24:400–5.
    1. Williams SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996;27:567–74.
    1. Wiltshire E, Thomas DW, Baghurst P, et al. Reduced total plasma homocyst(e)ine in children and adolescents with type 1 diabetes. J Pediatr. 2001;138:888–93.
    1. Wiltshire EJ, Gent R, Hirte C, Pena A, et al. Endothelial dysfunction relates to folate status in children and adolescents with type 1 diabetes. Diabetes. 2002;51:2282–6.
    1. Xi XP, Graf K, Goetze S, et al. Central role of the MAPK pathway in ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19:73–82.
    1. Xiang GD, He YS, Dai XJ, et al. Angiotensin-converting enzyme gene and the brachial artery endothelial dysfunction in type 2 diabetes without angiopathy. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2004;21:355–9.
    1. Yaqoob M, Patrick AW, McClelland P, et al. Relationship between markers of endothelial dysfunction, oxidant injury and tubular damage in patients with insulin-dependent diabetes mellitus. Clin Sci (Colch) 1993;85:557–62.
    1. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 2000;96:1723–32.
    1. Yu Y, Suo L, Yu H, et al. Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria. Diabetes Res Clin Pract. 2004;65:95–104.
    1. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA. 2001;286:1882–5.
    1. Zeng G, Nystrom FH, Ravichandran LV, et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000;101:1539–45.
    1. Zoppini G, Targher G, Cacciatori V, et al. Chronic cigarette smoking is associated with increased plasma circulating intercellular adhesion molecule 1 levels in young type 1 diabetic patients. Diabetes Care. 1999;22:1871–4.
    1. Zoukourian C, Wautier MP, Chappey O, et al. Endothelial cell dysfunction secondary to the adhesion of diabetic erythrocytes. Modulation by iloprost. Int Angiol. 1996;15:195–200.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner